Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor.

Major limitations of currently investigated αβT cells redirected against cancer by transfer of tumor-specific αβTCR arise from their low affinity, MHC restriction, and risk to mediate self-reactivity after pairing with endogenous α or βTCR chains. Therefore, the ability of a defined γ9δ2TCR to redirect αβT cells selectively against tumor cells was tested and its molecular interaction with a variety of targets investigated. Functional analysis revealed that a γ9δ2TCR efficiently reprograms both CD4(+) and CD8(+) αβT cells against a broad panel of cancer cells while ignoring normal cells, and substantially reduces but does not completely abrogate alloreactivity. γ9δ2TCR-transduced αβT cells reduced colony formation of progenitor cells of primary acute myeloid leukemia blasts and inhibited leukemia growth in a humanized mouse model. Thereby, metabolites of a dysregulated mevalonate pathway are targeted and the additional application of widely used biphosphonates is crucial for in vivo efficacy most likely because of its modulating effect on cytokine secretion of γ9δ2TCR-transduced αβT cells. Expression of NKG2D ligands and F1-ATPase contributed to the activity of γ9δ2TCR-transduced αβT cells but were not mandatory. In summary, γ9δ2 TCRs are an attractive alternative to broadly redirect αβT cells against cancer cells with both an improved efficacy and safety profile compared with currently used αβTCRs.

[1]  G. Dotti,et al.  Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. , 2010, Blood.

[2]  J. Barata,et al.  Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood γδ T cells , 2010, Haematologica.

[3]  M. Bonneville,et al.  γδ T cell effector functions: a blend of innate programming and acquired plasticity , 2010, Nature Reviews Immunology.

[4]  P. Vantourout,et al.  F1-Adenosine Triphosphatase Displays Properties Characteristic of an Antigen Presentation Molecule for Vγ9Vδ2 T Cells , 2010, The Journal of Immunology.

[5]  Hong Wang,et al.  Vγ2Vδ2 T Cell Receptor Recognition of Prenyl Pyrophosphates Is Dependent on All CDRs , 2010, The Journal of Immunology.

[6]  T. Schumacher,et al.  Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy , 2010, Nature Medicine.

[7]  J. Barata,et al.  The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity. , 2010, Blood.

[8]  M. Todaro,et al.  Vγ9Vδ2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells , 2010, The Journal of Immunology.

[9]  Yoshimasa Tanaka,et al.  Complete Remission of Lung Metastasis Following Adoptive Immunotherapy Using Activated Autologous γδ T-cells in a Patient with Renal Cell Carcinoma , 2010 .

[10]  Kenshi Suzuki,et al.  Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. , 2009, Experimental hematology.

[11]  Chi Ma,et al.  The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D. , 2009, Blood.

[12]  V. Marcu-Malina,et al.  Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors , 2009 .

[13]  R. Strong,et al.  Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain , 2009, The Journal of experimental medicine.

[14]  I. Holen,et al.  Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth , 2008, Anti-cancer drugs.

[15]  B. Alarcón,et al.  Different composition of the human and the mouse γδ T cell receptor explains different phenotypes of CD3γ and CD3δ immunodeficiencies , 2007, The Journal of experimental medicine.

[16]  B. Wollenberg,et al.  Lysis of a Broad Range of Epithelial Tumour Cells by Human γδ T Cells: Involvement of NKG2D ligands and T‐cell Receptor‐ versus NKG2D‐dependent Recognition , 2007 .

[17]  Ralf-Holger Voss,et al.  Facilitating matched pairing and expression of TCR chains introduced into human T cells. , 2007, Blood.

[18]  S. Rosenberg,et al.  Adoptive immunotherapy for cancer: building on success , 2006, Nature Reviews Immunology.

[19]  K. Besold,et al.  Cytomegalovirus interleukin-10 expression in infected cells does not impair MHC class I restricted peptide presentation on bystanding antigen-presenting cells. , 2006, Viral immunology.

[20]  M. Bonneville,et al.  Potentiation of Antigen-Stimulated Vγ9Vδ2 T Cell Cytokine Production by Immature Dendritic Cells (DC) and Reciprocal Effect on DC Maturation1 , 2006, The Journal of Immunology.

[21]  D. Kabelitz,et al.  Activation of Vγ9Vδ2 T Cells by NKG2D1 , 2005, The Journal of Immunology.

[22]  S. Xue,et al.  A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Neurath,et al.  Control Of Organ Transplant-Associated Graft-versus-Host Disease By Activated Host Lymphocyte Infusions , 2004, Transplantation.

[24]  P. Reimer,et al.  Gammadelta T cells for immune therapy of patients with lymphoid malignancies. , 2003, Blood.

[25]  Yoshimasa Tanaka,et al.  Requirement of Species-Specific Interactions for the Activation of Human γδ T Cells by Pamidronate1 , 2003, The Journal of Immunology.

[26]  G. De Libero,et al.  Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells , 2003, The Journal of experimental medicine.

[27]  M. Schuler,et al.  Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man , 2002, Gene Therapy.

[28]  M. Schuler,et al.  Successful Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients With Bladder Cancer by Intravesical Vector Instillation , 2002 .

[29]  Hans J. Stauss,et al.  Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer , 2001, Nature Immunology.

[30]  Jean-Jacques Fournié,et al.  Structure of a human γδ T-cell antigen receptor , 2001, Nature.

[31]  M. Wilhelm,et al.  Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma , 2000 .

[32]  K D Wittrup,et al.  In vitro evolution of a T cell receptor with high affinity for peptide/MHC. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. M. Izquierdo,et al.  A Conserved Mechanism for Controlling the Translation of β-F1-ATPase mRNA between the Fetal Liver and Cancer Cells* , 2000, The Journal of Biological Chemistry.

[34]  G. Favre,et al.  Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells. , 1999, Biochemical and biophysical research communications.

[35]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.

[36]  G. Favre,et al.  Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells. , 1998, The Biochemical journal.

[37]  J. Bodmer,et al.  IMGT, the international ImMunoGeneTics database , 1997, Nucleic Acids Res..

[38]  Mark M. Davis,et al.  The nature of major histocompatibility complex recognition by γδ T cells , 1994, Cell.

[39]  S. Leyvraz,et al.  Pharmacokinetics of pamidronate in patients with bone metastases. , 1992, Journal of the National Cancer Institute.

[40]  P. Stacpoole,et al.  In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma. , 1991, Journal of lipid research.

[41]  R. Demars,et al.  Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. , 1990, Science.

[42]  P. Vantourout,et al.  Ecto-F1-ATPase and MHC-class I close association on cell membranes. , 2008, Molecular immunology.

[43]  D. Kabelitz,et al.  Perspectives of gammadelta T cells in tumor immunology. , 2007, Cancer research.

[44]  Shamsul A. Khan,et al.  Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. , 2007, Blood.

[45]  Pedro Romero,et al.  Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. , 2005, Immunity.

[46]  B. Monsarrat,et al.  Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. , 2005, Immunity.

[47]  Yoshimasa Tanaka,et al.  Direct presentation of non-peptide prenyl pyrophosphate antigens to human γδ T cells , 1996 .